318 related articles for article (PubMed ID: 23828904)
1. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
2. The Role of LOX and LOXL2 in the Pathogenesis of an Experimental Model of Choroidal Neovascularization.
Van Bergen T; Spangler R; Marshall D; Hollanders K; Van de Veire S; Vandewalle E; Moons L; Herman J; Smith V; Stalmans I
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5280-9. PubMed ID: 26258612
[TBL] [Abstract][Full Text] [Related]
3. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
4. The role of LOX and LOXL2 in scar formation after glaucoma surgery.
Van Bergen T; Marshall D; Van de Veire S; Vandewalle E; Moons L; Herman J; Smith V; Stalmans I
Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5788-96. PubMed ID: 23821193
[TBL] [Abstract][Full Text] [Related]
5. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
[TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
Barry-Hamilton V; Spangler R; Marshall D; McCauley S; Rodriguez HM; Oyasu M; Mikels A; Vaysberg M; Ghermazien H; Wai C; Garcia CA; Velayo AC; Jorgensen B; Biermann D; Tsai D; Green J; Zaffryar-Eilot S; Holzer A; Ogg S; Thai D; Neufeld G; Van Vlasselaer P; Smith V
Nat Med; 2010 Sep; 16(9):1009-17. PubMed ID: 20818376
[TBL] [Abstract][Full Text] [Related]
7. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
8. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor.
Rodriguez HM; Vaysberg M; Mikels A; McCauley S; Velayo AC; Garcia C; Smith V
J Biol Chem; 2010 Jul; 285(27):20964-74. PubMed ID: 20439985
[TBL] [Abstract][Full Text] [Related]
9. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP.
Pratheeshkumar P; Kuttan G
Eur J Pharmacol; 2011 Apr; 656(1-3):10-8. PubMed ID: 21256125
[TBL] [Abstract][Full Text] [Related]
10. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
11. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
12. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
[TBL] [Abstract][Full Text] [Related]
13. The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation.
Lugassy J; Zaffryar-Eilot S; Soueid S; Mordoviz A; Smith V; Kessler O; Neufeld G
J Biol Chem; 2012 Jan; 287(5):3541-9. PubMed ID: 22157764
[TBL] [Abstract][Full Text] [Related]
14. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
15. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
16. The role of angiogenesis in solid tumours: an overview.
Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
[TBL] [Abstract][Full Text] [Related]
17. Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Kim SB; Lee D; Jeong JW; Kim C; Park D; Kim MG
Mol Cells; 2010 Jun; 29(6):617-23. PubMed ID: 20652801
[TBL] [Abstract][Full Text] [Related]
18. Are tumours angiogenesis-dependent?
Verheul HM; Voest EE; Schlingemann RO
J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
20. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
